Loading…
← CockpitCompetitor Analysis › 600222.SS Henan Taloph Pharmaceutical Stock Co. Ltd. Class AOpen in the cockpit ↗

Henan Taloph Pharmaceutical Stock Co. Ltd. Class A600222.SSCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Major
Momentum weak 38
Mkt cap
$497M
US dollars, full cap
Free float
77%
of shares outstanding
$/day
$10.3M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-2.7 pp
WACC 7.4%
Hurdle
+12 pp
Req g minus delivered
Close · CNYCN¥6.12
1D-0.5%
1W-6.7%
1M-13.7%
3M-24.2%
6M-21.1%
YTD-7.0%
1Y-5.4%
ATR %4.1%
52w lowhigh35.2% off high

What Henan Taloph Pharmaceutical Stock does

Employees: 2,084

Henan Taloph Pharmaceutical Stock at a glance

Size Henan Taloph Pharmaceutical Stock (600222.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $497M, the 3714th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥6.12 on 18 Nov 2026.

Performance Over six months the shares fell 21.1%, against -18.4% for the median peer and -20.0% for the China market (cap-weighted) — 9th lowest of 21 in its peer set.

Growth Revenue fell 4.7% over the last twelve months (peer median +9.8%); the operating margin is 6.8% (peer median 10.0%).

Valuation It trades at 2.5× enterprise value to sales against a peer median of 4.0× (7th cheapest of 20).

Price implies For today's price to make sense, revenue must grow about 17% a year for seven years (Req g). Recent delivered growth is +4%, so the hurdle is +12 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 2.7 points below its cost of capital (7.4% WACC).

Relative performance

8010021 May 202621 Aug 202618 Nov 2026Peer median 83600222.SS 79
Six months, rebased to 100: Henan Taloph Pharmaceutical Stock against the median of its 20 peers (local-currency closes).

Henan Taloph Pharmaceutical Stock financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥1.70BCN¥1.75BCN¥1.94BCN¥2.06BCN¥1.96B
Revenue growth—-10%-6%+6%—
Gross profitCN¥495MCN¥453MCN¥461MCN¥534MCN¥444M
EBITDAn/aCN¥199MCN¥147MCN¥160MCN¥59.5M
Net incomeCN¥50.9MCN¥60.0MCN¥50.5MCN¥43.6M-CN¥72.2M
Free cash flowCN¥46.0MCN¥64.8M-CN¥74.2MCN¥55.7M-CN¥132M
Capital expenditureCN¥16.7MCN¥21.1MCN¥37.2MCN¥43.1MCN¥66.6M
Total debtCN¥1.24BCN¥1.31BCN¥1.09BCN¥819MCN¥775M

Quarterly statements and history in the cockpit →

Henan Taloph Pharmaceutical Stock competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+50%+100%0%+20%TKNO600513003090AARTIDRUGSGYRE0021071666603207GUJTHEMINDP301277003020EGTXRGNXHNSA600624600222.SS6-month return →1-month return →
Up and to the right = strong over both horizons. Henan Taloph Pharmaceutical Stock is the large dot.

Fundamentals: revenue growth against valuation

-20%0%+20%+40%+60%0×25×50×75×TKNO600513003090AARTIDRUGS0021071666603207GUJTHEM300584003020EGTX688373HNSA600624600222.SSRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Henan Taloph Pharmaceutical Stock is the large dot.

Capital: growth delivered against growth the price implies

0%+50%+100%0%50%100%AARTIDRUGS0021071666603207301277HNSA600222.SSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Henan Taloph Pharmaceutical Stock is the large dot.

Henan Taloph Pharmaceutical Stock competitors and peer comparison

How Henan Taloph Pharmaceutical Stock compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Henan Taloph Pharmaceutical Stock against its 20 peers (data as of 18 Nov 2026)
Measure600222.SSPeer medianRank in peer set
1-month return-13.7%-2.1%4th lowest of 21
6-month return-21.1%-18.4%9th lowest of 21
Distance from 52-week high-35.2%-37.4%10th highest of 21
Revenue growth (TTM)-4.7%+9.8%5th lowest of 20
Operating margin6.8%10.0%10th lowest of 20
EV / Sales2.5×4.0×7th cheapest of 20
Growth the price implies (Req g, 7 yrs)16.7%-0.7%2nd most demanding of 9
Growth delivered (Del g)+4.4%+7.0%4th lowest of 9
Hurdle (Req g minus delivered)+12.3 pp-6.6 pp2nd most demanding of 9
ROIC minus cost of capital-2.7 pp-2.4 pp9th lowest of 18

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Henan Taloph Pharmaceutical Stock 600222.SSChina$497M-21%-5%7%2.5×16.7%+4.4%
Alpha Teknova TKNOUnited States$496M+113%+15%-32%11.0×n/an/a
Jiangsu Lianhuan Pharmaceutical 600513.SSChina$496M-41%+14%0%1.8×n/an/a
Daewoong 003090.KSSouth Korea$495M-28%+6%11%0.9×n/an/a
Aarti Drugs AARTIDRUGS.NSIndia$494M+34%+15%11%1.8×22.1%+3.5%
Gyre Therapeutics GYREUnited States$500M-28%+14%-18%4.0×n/an/a
Shandong Wohua Pharmaceutical 002107.SZChina$493M-20%-4%18%3.7×5.9%-4.1%
Tong Ren Tang Technologies 1666.HKHong Kong$491M-19%-14%12%0.6×-17.2%+6.3%
Shanghai Xiao Fang Pharmaceutical 603207.SSChina$503M-17%+10%39%4.8×-5.4%+7.6%
Gujarat Themis Biosyn GUJTHEM.NSIndia$505M+2%+18%39%27.2×n/an/a
Indaptus Therapeutics INDPUnited States$505M+147%n/an/an/an/an/a
Newland Pharmaceutical 301277.SZChina$488M-22%+9%11%3.5×8.9%+9.1%
Nanjing Hicin Pharmaceutical 300584.SZChina$487M-29%+32%17%4.3×3.3%-1.1%
Hefei Lifeon Pharmaceutical 003020.SZChina$486M-21%-1%10%2.0×n/an/a
Egetis Therapeutics EGTX.STSweden$509M+76%+27%-645%71.0×n/an/a
Xizang Weixinkang Pharmaceutical 603676.SSChina$513M-22%-8%16%2.3×-6.1%+9.6%
Shanghai MicuRx Pharmaceutical 688373.SSChina$481M-8%+23%-61%19.0×n/an/a
REGENXBIO RGNXUnited States$480M+22%-5%-120%3.1×n/an/a
Hansa Biopharma HNSA.STSweden$479M+39%+69%-190%14.9×-4.7%+105.3%
Shanghai Fudan Forward S&T 600624.SSChina$478M0%-14%-34%6.4×n/an/a
Beijing Science Sun Pharmaceutical 300485.SZChina$517M-29%-11%-8%5.6×n/an/a

Questions

Which companies are Henan Taloph Pharmaceutical Stock's closest peers?
The cockpit's peer set: Alpha Teknova (TKNO), Jiangsu Lianhuan Pharmaceutical (600513.SS), Daewoong (003090.KS), Aarti Drugs (AARTIDRUGS.NS), Gyre Therapeutics (GYRE), Shandong Wohua Pharmaceutical (002107.SZ), Tong Ren Tang Technologies (1666.HK), Shanghai Xiao Fang Pharmaceutical (603207.SS).
Is Henan Taloph Pharmaceutical Stock expensive compared with its peers?
On ev / sales it trades at 2.5× against a peer median of 4.0×, 7th cheapest of 20 in its peer set. For today's price to make sense, revenue must grow about 17% a year for seven years (Req g). Recent delivered growth is +4%, so the hurdle is +12 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Henan Taloph Pharmaceutical Stock stock performed?
Over six months to 18 Nov 2026 the shares returned -21.1% against -18.4% for the median peer; over one year -5.4%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.